Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Distribution of High-Risk Human Papillomavirus (HPV) Genotypes in India vs World Health Organization Regions and Countries: Implications for HPV Vaccination.

Ochsner journal·2026
Same author

Current Practices and Variations in the Use of FDG-PET and Bone Marrow Biopsy in Ewing Sarcoma Diagnosis: A Survey of Provider Recommendations.

Journal of pediatric hematology/oncology·2026
Same author

Optimizing Sequential Targeted Therapies in Advanced Renal Cell Carcinoma Using Patient-Derived Orthotopic Xenograft Mouse Avatars.

Cancers·2026
Same author

Evaluation of dose-response relationships between smoking tobacco, alcohol consumption and oral cancer: a systematic review and meta-analysis.

BMC public health·2026
Same author

Impact of ultrahypofractionated adjuvant regional nodal radiotherapy on patient-reported quality of life: the HYPORT adjuvant trial (NCT03788213).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Caring for the caregivers: breast and cervical cancer screening among informal caregivers of cancer patients - a scoping review.

BMC primary care·2026
Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026
Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026
Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026
Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026
Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Radiobiotherapy in Osteosarcoma: A State-Based Educational Framework for Strategy Selection and Trial Design.

Srinivasan Vijayakumar1,2,3,4, Shirley Lewis2, Marc Matrana5,6,7,8,9,10,11

  • 1Department of Radiology, Ochsner Clinic Foundation and Xavier Ochsner College of Medicine, New Orleans, LA 70112, USA.

Current Oncology (Toronto, Ont.)
|June 25, 2026
PubMed
Summary
This summary is machine-generated.

A new state-based framework integrates radiotherapy, including stereotactic body radiotherapy (SBRT/SABR) and spatially fractionated radiotherapy (SFRT), into osteosarcoma treatment. This approach considers dynamic disease variables for better treatment selection and clinical trial design.

Keywords:
clinical trial designeducational frameworkhypothesis generationosteosarcomaradiobiotherapyspatially fractionated radiotherapystate-based decision-makingstereotactic body radiotherapy

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Related Experiment Videos

Last Updated: Jun 26, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Area of Science:

  • Oncology
  • Radiation Oncology
  • Translational Medicine

Background:

  • Osteosarcoma is a complex cancer with plateauing survival rates despite multimodal therapy.
  • Its genetic complexity, including structural variations and clonal evolution, limits precision oncology.
  • Novel frameworks are needed to align treatment with evolving disease characteristics.

Purpose of the Study:

  • To propose a state-based framework for integrating radiotherapy into osteosarcoma management.
  • To guide clinical trial design by emphasizing dynamic disease variables over static staging.
  • To explore radiotherapy's role as a biologic intervention beyond local control.

Main Methods:

  • Narrative educational review synthesizing evidence from osteosarcoma biology, radiobiology, and translational oncology.
  • Development of a state-based framework considering disease burden, progression tempo, systemic response, and local control feasibility.
  • Integration of stereotactic body radiotherapy (SBRT/SABR) and spatially fractionated radiotherapy (SFRT) into the framework.

Main Results:

  • Radiotherapy is presented as a local control modality and a biologic intervention affecting tumor microenvironment.
  • Potential benefits include local eradication and immune modulation; limitations involve abscopal response rarity and systemic signaling risks.
  • Dose, fractionation, and spatial distribution of radiotherapy influence its biologic effects.

Conclusions:

  • The proposed framework supports state-stratified, biomarker-embedded clinical trials for osteosarcoma.
  • Highlights novel endpoints like circulating tumor DNA dynamics and immune/myeloid signatures.
  • Frames radiobiotherapy as an educational paradigm for hypothesis generation and learning-oriented trial designs.